Positive trial results for Biogen Idec's MS drug BG-12 The Pharma Letter In fact, interest in BG-12, along with Biogen Idec's PEG-Avonex, Abbott/Biogen Idec's daclizumab and Roche/Genentech's ocrelizumab, has increased significantly compared to a year ago. “The publication of both dimethyl fumarate pivotal studies in NEJM ... |
